Latest Publications

Pflügler S, Svinka J, Scharf I, Crncec I, Filipits M, Charoentong P, et al. IDO1+ Paneth cells promote immune escape of colorectal cancer. Commun Biol. 2020;3. doi: 10.1038/s42003-020-0989-y

Paur J, Valler M, Sienel R, Taxauer K, Holzmann K, Marian B, et al. Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behavior of hepatocellular carcinoma. Liver Int. 2020. doi: 10.1111/liv.14505 3.

Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, et al. Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup. Clin Cancer Res. 2020. doi: 10.1158/1078-0432.CCR-19-3573

Oberhuber M, Pecoraro M, Rusz M, Oberhuber G, Wieselberg M, Haslinger P, et al. STAT3-dependent analysis reveals PDK4 as independent predictor of recurrence in prostate cancer. Mol Syst Biol. 2020;16: e9247. doi: 10.15252/msb.20199247

Englinger B, Laemmerer A, Moser P, Kallus S, Röhrl C, Pirker C, et al. Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib. Int J Cancer. 2020. doi: 10.1002/ijc.32924

Klufa J, Bauer T, Hanson B, Herbold C, Starkl P, Lichtenberger B, et al. Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy. Science Translational Medicine. 2019;11. doi: 10.1126/scitranslmed.aax2693

Tolios A, De Las Rivas J, Hovig E, Trouillas P, Scorilas A, Mohr T. Computational approaches in cancer multidrug resistance research: identification of potential biomarkers, drug targets and drug-target interactions. Drug Resistance Updates. 2019; 100662. doi: 10.1016/j.drup.2019.100662

Wagner G, Lindroos-Christensen J, Einwallner E, Husa J, Zapf T-C, Lipp K, et al. HO-1 inhibits preadipocyte proliferation and differentiation at the onset of obesity via ROS dependent activation of Akt2. Sci Rep. 2017;7: 40881. doi: 10.1038/srep40881

Jomrich G, Hudec X, Harpain F, Winkler D, Timelthaler G, Mohr T, et al. Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas. Cells. 2019;8: 1092. doi: 10.3390/cells8091092

Oberhuber M, Pecoraro M, Rusz M, Oberhuber G, Wieselberg M, Haslinger P, et al. STAT3-dependent systems-level analysis reveals PDK4 as an independent predictor of biochemical recurrence in prostate cancer. bioRxiv. 2019; 770701. doi: 10.1101/770701

Paulitschke V, Eichhoff O, Gerner C, Paulitschke P, Bileck A, Mohr T, et al. Proteomic identification of a marker signature for MAPKi resistance in melanoma. EMBO J. 2019; e95874. doi: 10.15252/embj.201695874

Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, et al. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis. 2018;39: 534–545. doi: 10.1093/carcin/bgy018

Linder M, Glitzner E, Srivatsa S, Bakiri L, Matsuoka K, Shahrouzi P, et al. EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling. EMBO Mol Med. 2018;10. doi: 10.15252/emmm.201809408

Hager S, Korbula K, Bielec B, Grusch M, Pirker C, Schosserer M, et al. The thiosemicarbazone Me2NNMe2 induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition. Cell Death Dis. 2018;9: 1052. doi: 10.1038/s41419-018-1102-z

Heilos D, Röhrl C, Pirker C, Englinger B, Baier D, Mohr T, et al. Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins. Oncotarget. 2018;9: 25661–25680. doi: 10.18632/oncotarget.25432

Koch M, Umek W, Hanzal E, Mohr T, Seyfert S, Koelbl H, et al. Serum proteomic pattern in female stress urinary incontinence. Electrophoresis. 2018. doi: 10.1002/elps.201700423

Crnčec I, Modak M, Gordziel C, Svinka J, Scharf I, Moritsch S, et al. STAT1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer. Mol Oncol. : n/a-n/a. doi: 10.1002/1878-0261.12178

Mohr T, Haudek-Prinz V, Slany A, Grillari J, Micksche M, Gerner C. Proteome profiling in IL-1β and VEGF-activated human umbilical vein endothelial cells delineates the interlink between inflammation and angiogenesis. PLoS ONE. 2017;12: e0179065. doi: 10.1371/journal.pone.0179065

Jacobi N, Seeboeck R, Hofmann E, Schweiger H, Smolinska V, Mohr T, et al. Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget. 2017;8: 107423–107440. doi: 10.18632/oncotarget.22475

Ghassemi S, Vejdovszky K, Sahin E, Ratzinger L, Schelch K, Mohr T, et al. FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo. Oncotarget. 2017;8: 87750–87762. doi: 10.18632/oncotarget.21184

Drev D, Bileck A, Erdem ZN, Mohr T, Timelthaler G, Beer A, et al. Proteomic profiling identifies markers for inflammation-related tumor-fibroblast interaction. Clin Proteomics. 2017;14: 33. doi: 10.1186/s12014-017-9168-7

Schoenhacker-Alte B, Mohr T, Pirker C, Kryeziu K, Kuhn P-S, Buck A, et al. Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis. Cancer Lett. 2017. doi: 10.1016/j.canlet.2017.07.009

Gojo J, Lötsch D, Spiegl-Kreinecker S, Pajtler KW, Neumayer K, Korbel P, et al. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro-oncology. 2017. doi: 10.1093/neuonc/nox027

Englinger B, Mair M, Miklos W, Pirker C, Mohr T, van Schoonhoven S, et al. Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance. Br J Cancer. 2017;116: 489–500. doi: 10.1038/bjc.2016.449

Themanns M, Mueller KM, Kessler SM, Golob-Schwarzl N, Mohr T, Kaltenecker D, et al. Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice. Scientific Reports. 2016;6: 34719. doi: 10.1038/srep34719

Koch M, Mitulovic G, Hanzal E, Umek W, Seyfert S, Mohr T, et al. Urinary proteomic pattern in female stress urinary incontinence: a pilot study. Int Urogynecol J. 2016. doi: 10.1007/s00192-016-3033-5

Englinger B, Lötsch D, Pirker C, Mohr T, van Schoonhoven S, Boidol B, et al. Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression. Oncotarget. 2016. doi: 10.18632/oncotarget.10324

Kryeziu K, Pirker C, Englinger B, Schoonhoven S van, Spitzwieser M, Mohr T, et al. Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells. Oncotarget. 2016;5. Available:  http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=8415

Pathria P, Gotthardt D, Prchal-Murphy M, Putz E-M, Holcmann M, Schlederer M, et al. Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. OncoImmunology. 2015;4: e998529. doi: 10.1080/2162402X.2014.998529

Mathieu V, Chantôme A, Lefranc F, Cimmino A, Miklos W, Paulitschke V, et al. Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase. Cell Mol Life Sci. 2015. doi: 10.1007/s00018-015-1902-6

Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, et al. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat Commun. 2015;6. doi: 10.1038/ncomms7285

Spiegl-Kreinecker S, Lötsch D, Ghanim B, Pirker C, Mohr T, Laaber M, et al. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol. 2015; nov010. doi: 10.1093/neuonc/nov010

Dornetshuber-Fleiss R, Heilos D, Mohr T, Richter L, Süssmuth RD, Zlesak M, et al. The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo. Biochemical Pharmacology. 2015;93: 318–331. doi: 10.1016/j.bcp.2014.12.013

Schosserer M, Minois N, Angerer TB, Amring M, Dellago H, Harreither E, et al. Methylation of ribosomal RNA by NSUN5 is a conserved mechanism modulating organismal lifespan. Nat Commun. 2015;6: 6158. doi: 10.1038/ncomms7158